

ONCOCYTE TO PARTICIPATE AT NEEDHAM VIRTUAL CANCER DIAGNOSTICS CONFERENCE

Aug 13, 2020

IRVINE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that company management will participate in the 1-on-1 meetings at the upcoming Needham Virtual Cancer Diagnostics 1x1 Conference on Tuesday, August 18, 2020.

About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also developing DetermalO™, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies.

DetermaRx and DetermalO are trademarks of Oncocyte Corporation.

Investor Contact

Bob Yedid LifeSci Advisors, LLC 646-597-6989 bob@lifesciadvisors.com

Media Contact

Cait Williamson, Ph.D. LifeSci Communications, LLC 646-751-4366 cait@lifescicomms.com

Source: Oncocyte Corporation



Source: OncoCyte Corporation

